Each sustained-release tablet contains Aceclofenac 200 mg.

Dolowin SR is a sustained-release formulation of Aceclofenac, a nonsteroidal anti-inflammatory drug (NSAID) with potent analgesic and anti-inflammatory properties. The sustained-release technology provides prolonged therapeutic drug levels, enabling convenient once-daily dosing for effective management of chronic inflammatory and painful musculoskeletal conditions. It helps reduce joint pain, stiffness, inflammation, and improves mobility while enhancing patient compliance.

Dolowin SR is indicated for the relief of pain and inflammation associated with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It is suitable for the long-term management of chronic inflammatory musculoskeletal disorders requiring sustained analgesic and anti-inflammatory therapy.

Aceclofenac is a nonsteroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties. Its therapeutic action is primarily mediated through inhibition of cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins that are responsible for pain, inflammation, and swelling. The sustained-release formulation maintains prolonged plasma concentrations, providing continuous symptom control throughout the day.

The recommended dosage is one sustained-release tablet once daily, preferably with or after food, or as directed by the treating physician.

Dolowin SR is contraindicated in patients with known hypersensitivity to aceclofenac or any component of the formulation. It should not be administered to patients with active or recurrent peptic ulcer disease or gastrointestinal hemorrhage, particularly those with two or more confirmed episodes of ulceration or bleeding.